Gonadorelin

Dienogest was compared to placebo, no treatment, gonadorelin analogues, combined oral contraceptives, and other progestogens.; The review included five studies and used GRADE to assess evidence quality.; Ectopic endometrial tissue occurs in 2-6% of reproductive-age women and up to 60% of those with dysmenorrhoea.; Symptoms may not correlate with laparoscopic findings.

Menorrhagia limits normal activities and causes anaemia in two-thirds of women with objective blood loss ≥80 mL per cycle.; Prostaglandin disorders may be linked to idiopathic menorrhagia and heavy bleeding from fibroids, adenomyosis, or IUDs.; Fibroids found in 10% of women with menorrhagia overall, 40% with severe menorrhagia; half of hysterectomies for menorrhagia reveal a normal uterus.; Review included 39 systematic reviews, RCTs, or observational studies with GRADE evaluation for interventions.

Cyclical breast pain resolves spontaneously in 20-30% of women but recurs in 60%.; Non-cyclical pain responds poorly to treatment but resolves spontaneously in half of women.; The review assessed 18 interventions including antibiotics, NSAIDs, and hormonal treatments.

Fibroids may be asymptomatic or cause menorrhagia, pain, infertility, or recurrent pregnancy loss.; Risk factors include obesity, no children, and no long-term oral contraceptive use.; Fibroids tend to shrink or fibrose after menopause.; Interventions evaluated include medical treatments, preoperative medical therapies, and surgical options such as hysterectomy, myomectomy, and uterine artery embolisation.

Median survival from metastatic breast cancer is 12 months without treatment, but young people can survive up to 20 years.; First-line hormonal treatments include tamoxifen, ovarian ablation, progestins, and aromatase inhibitors.; First-line chemotherapy options include taxane-based combinations and non-taxane combinations, with or without monoclonal antibodies like trastuzumab.; Treatments for bone metastases include bisphosphonates, and for spinal or cerebral metastases include radiotherapy and surgery.

What is Gonadorelin?

**Mechanism of Action** Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on anterior pituitary gonadotroph cells, stimulating the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This actio

How does Gonadorelin work?

Synthetic GnRH decapeptide that stimulates pituitary LH and FSH release; used diagnostically and to support gonadal function.

What is the research status of Gonadorelin?

Gonadorelin is currently classified as approved, with 295 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Gonadorelin?

Gonadorelin has a molecular weight of approximately 1182.3 g/mol (formula C55H75N17O13).